Patients with plethora can get COVID-19 vaccine if well controlled

        The epidemic is severe. There have been many cases of thrombosis after vaccination with AZ vaccine in Europe. Taiwan also has the first case of thrombosis and low platelet syndrome after vaccination with AZ vaccine. Patients with plethora often have questions about whether they can get the vaccination?
        Scientists are still actively studying whether COVID-19 vaccine causes thrombosis. Eastern human body is less prone to thrombosis. Patients with plethora have a higher risk of thrombosis, can they be vaccinated with AZ vaccine? At present, the clinical trials of various new crown vaccines are not specifically conducted on patients with blood diseases, but the British Society of Hematology, which has administered the most AZ vaccines, recommends that the hematocrit is well-controlled in patients with plethora, less than 45% of men and less than 42% of women , You can administer COVID-19 vaccine.
        Hyperemia is a common name for "polycythemia vera" and is a rare blood disease. There are about 140 new cases in Taiwan each year. Patients may have tight necks, high blood pressure, or flushing of the face. Some patients have no symptoms. They were accidentally discovered during the health examination. After the conditions such as smoking, cardiopulmonary disease or sleep cessation have been ruled out, genetic testing and bone marrow examination are recommended.
        In the past, plethysmia was diagnosed through bone marrow biopsy. Nowadays, genetic testing technology has improved. It is found that 99% of plethora patients have JAK2 gene mutations. As long as blood is drawn, it can be used as a diagnostic basis, allowing more patients to be diagnosed and treated accordingly.
        Traditionally, bloodletting or medication is used to reduce the patient's hematocrit, which can reduce the risk of stroke, but it cannot solve the genetic variation, and the complications cannot be eradicated, such as skin itching. At present, patients can use the new long-acting interferon therapy to control the hematocrit, reduce the number of the mutant gene JAK2, and even the patient's troubled itching will disappear.
        If hyperemia is not handled well, there is a risk of stroke, but if the treatment is closely followed up, it can be well controlled. Early detection and early treatment will allow patients to have a healthy and normal life.